Hussein A. Tawbi, MD, PhD

A 3 year survival update on the RELATIVITY-047 trial (NCT03470922), a global, randomized, double-blind phase 2/3 study comparing nivolumab plus relatlimab vs nivolumab in previously untreated metastatic or unresectable stage III or IV melanoma.

Hussein A. Tawbi, MD, PhD, discusses the 2-year findings from the phase 2/3 RELATIVITY-047 trial of nivolumab plus relatlimab in treatment-naïve patients with metastatic or unresectable melanoma.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in patients with metastatic or unresectable melanoma, according to data from the phase 2/3 RELATIVITY-047 trial.

Hussein A. Tawbi, MD, PhD, discusses the utilization of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Hussein A. Tawbi, MD, PhD, discusses the FDA approval of relatlimab plus nivolumab in unresectable or metastatic melanoma.

Hussein A. Tawbi, MD, PhD, discusses the safety profile of relatlimab plus nivolumab in advanced melanoma.

Hussein A. Tawbi, MD, PhD, discusses the efficacy of relatlimab plus nivolumab in patients with advanced melanoma.

Hussein A. Tawbi, MD, PhD, discusses future research efforts in melanoma.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses unmet needs in melanoma.

Hussein A. Tawbi, MD, PhD, associate professor of medicine, The University of Texas MD Anderson Cancer Center, discusses evolving treatment for patients with melanoma.

Hussein A. Tawbi, MD, PhD, associate professor, The University of Texas MD Anderson Cancer Center, discusses the promise of checkpoint inhibition in the treatment of melanoma.